百奥赛图宣布Tubulis签署抗体许可协议以推进ADC疗法开发

新浪财经
Sep 16

(来源:百奥赛图)中国北京,2025年9月16日—百奥赛图(北京)医药科技股份有限公司(百奥赛图,股票代码:02315.HK),一家创新技术驱动新药研发的国际性生物技术公司,今日宣布Tubulis,一家致力于开发新一代抗体偶联药物(ADC)的生物技术公司已签署一项抗体许可协议,利用百奥赛图自主开发的全人抗体推进其ADC产品的研发和商业化。此次许可协议源自双方此前达成的研究合作与选择权协议,旨在基于...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10